With regard to progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who were resistant to aromatase inhibitors (AIs), there was no statistical superiority of palbociclib (Ibrance) plus endocrine therapy (ET) over capecitabine, according to results from the phase 3 PEARL study (NCT02028507), published in Annals of Oncology.1
However, the combination of palbociclib and ET did demonstrate a more favorable safety profile and improved quality of life among this patient population.
“In addition, while the PEARL trial did not meet its coprimary objectives, it still provides evidence and suggestions for the management of hormone receptor–positive AI-resistant MBC,” wrote the study authors, who were led by Miguel Martin, MD, PhD.
The randomized, multicenter, international, open-label, controlled phase 3 PEARL study evaluated patients with AI-resistant MBC in 2…
